LON:BPCR - Biopharma Credit Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 1.05 0.00 (0.00 %)
(As of 06/22/2018 04:00 PM ET)
Previous CloseGBX 1.04
Today's RangeGBX 1.04 - GBX 1.05
52-Week RangeGBX 1 - GBX 1.13
Volume14,160 shs
Average Volume64,237 shs
Market Capitalization£937.11 million
P/E RatioN/A
Dividend YieldN/A
BioPharma Credit PLC, an investment trust, invests in interest-bearing debt assets secured by royalties or other cash flows derived from the royalties and sales of life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.

Receive BPCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Asset Management
SectorFinancial Services


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins82.95%
Return on Equity5.84%
Return on Assets5.81%


Outstanding Shares761,880,000

Biopharma Credit (LON:BPCR) Frequently Asked Questions

What is Biopharma Credit's stock symbol?

Biopharma Credit trades on the London Stock Exchange (LON) under the ticker symbol "BPCR."

How often does Biopharma Credit pay dividends? What is the dividend yield for Biopharma Credit?

Biopharma Credit announced a dividend on Thursday, May 24th. Stockholders of record on Thursday, May 31st will be paid a dividend of GBX 0.01 per share on Friday, June 29th. This represents a dividend yield of 1.3%. The ex-dividend date of this dividend is Thursday, May 31st. The official announcement can be accessed at this link. View Biopharma Credit's Dividend History.

Who are some of Biopharma Credit's key competitors?

Who are Biopharma Credit's key executives?

Biopharma Credit's management team includes the folowing people:
  • Mr. Pedro Gonzalez de Cosio, Investment Mang.
  • Mr. Pablo G. Legorreta, Investment Mang.
  • Mr. Martin G. Friedman, Investment Mang. (Age 53)

Has Biopharma Credit been receiving favorable news coverage?

News articles about BPCR stock have been trending somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biopharma Credit earned a media sentiment score of 0.14 on Accern's scale. They also gave news headlines about the company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Biopharma Credit?

Shares of BPCR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Biopharma Credit's stock price today?

One share of BPCR stock can currently be purchased for approximately GBX 1.05.

How big of a company is Biopharma Credit?

Biopharma Credit has a market capitalization of £937.11 million.

MarketBeat Community Rating for Biopharma Credit (BPCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Biopharma Credit and other stocks. Vote "Outperform" if you believe BPCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.